CompletedPhase 4

Enhancing the A in SAFE for Trachoma

South Sudan34,630 participantsStarted 2022-05-04

Plain-language summary

This study will assess the cost and feasibility of two strategies of enhanced Mass Drug Administration (MDA) of Zithromax to treat trachoma in the Republic of South Sudan. The secondary objectives of this study are to measure trachoma infection outcomes during the 12-month follow-up period among children up to 9 years of age.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria for Villages: * The village must be located in a district eligible for annual MDA with azithromycin under WHO treatment guidelines. * The village representatives' consent to participation in the study. Individual consent will also be obtained for each individual within the study. Inclusion Criteria for Children in Enhanced MDA Strategy 1: * Children aged 6 months to 9 years of age * Consent for child inclusion is obtained by the parent/guardian and adequate provisions are made to solicit assent from the child. Exclusion Criteria: * none

What they're measuring

Coverage Among Young Children

Timeframe: Up to 12 months

Number of Participants Missing Antibiotic Treatment Round

Timeframe: Up to 12 months

Acceptability

Timeframe: Up to 12 months

Cost

Timeframe: Up to 12 months

Trial details

NCT IDNCT05634759

SponsorEmory University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-08-05

View on ClinicalTrials.gov More Trachoma trials